AbstractBackgroundDual antiplatelet therapy is the cornerstone in the management of acute coronary syndromes (ACS) and prevention of stent thrombosis (ST). Genetic polymorphisms in CYP2C19 gene involved in hepatic activation of clopidogrel leads to clopidogrel non-responsiveness and may influence clinical outcomes. These polymorphisms in CYP2C19 gene and their impact on clinical outcome in coronary artery disease (CAD) have not been studied in Indian population.MethodsWe studied 110 consecutive patients (mean age 55.7 ± 10.7 years; 90% male) taking clopidogrel with angiographically proven CAD for various genetic polymorphisms in CYP2C19 gene. Relationship between loss of function mutation and clinical presentation with recurrent ACS includi...
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug...
SummaryBackground and purposeCYP2C19*2 loss-of-function allele in Caucasians may be associated with ...
Cytochrome P450 2C19 (CYP2C19) *2 (681G>A; rs4244285) and CYP2C19*3 (636G>A; rs4986893) null alleles...
Background: Dual antiplatelet therapy is the cornerstone in the management of acute coronary syndrom...
AbstractBackgroundDual antiplatelet therapy is the cornerstone in the management of acute coronary s...
Clopidogrel plays a crucial role in preventing thrombotic events in patients undergoing percutaneous...
<p><strong>BACKGROUND:</strong> The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major p...
Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid i...
Objectives: To find out the prevalence of CYP2C19*2 genetic polymorphism in ischemic heart disease p...
Introduction: Antithrombotic agents are the basic therapeutic option for patients with arterial thro...
AbstractAimCYP2C19 polymorphism modulates platelet reactivity in coronary artery disease patients wi...
Background: To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel res...
AbstractAims/objectiveInfluence of genetic variations on the response of clopidogrel, an antiplatele...
Chonlaphat Sukasem,1 Ramaimon Tunthong,2 Montri Chamnanphon,1 Siwalee Santon,1 Thawinee Jantararoung...
Background: To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel res...
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug...
SummaryBackground and purposeCYP2C19*2 loss-of-function allele in Caucasians may be associated with ...
Cytochrome P450 2C19 (CYP2C19) *2 (681G>A; rs4244285) and CYP2C19*3 (636G>A; rs4986893) null alleles...
Background: Dual antiplatelet therapy is the cornerstone in the management of acute coronary syndrom...
AbstractBackgroundDual antiplatelet therapy is the cornerstone in the management of acute coronary s...
Clopidogrel plays a crucial role in preventing thrombotic events in patients undergoing percutaneous...
<p><strong>BACKGROUND:</strong> The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major p...
Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid i...
Objectives: To find out the prevalence of CYP2C19*2 genetic polymorphism in ischemic heart disease p...
Introduction: Antithrombotic agents are the basic therapeutic option for patients with arterial thro...
AbstractAimCYP2C19 polymorphism modulates platelet reactivity in coronary artery disease patients wi...
Background: To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel res...
AbstractAims/objectiveInfluence of genetic variations on the response of clopidogrel, an antiplatele...
Chonlaphat Sukasem,1 Ramaimon Tunthong,2 Montri Chamnanphon,1 Siwalee Santon,1 Thawinee Jantararoung...
Background: To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel res...
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug...
SummaryBackground and purposeCYP2C19*2 loss-of-function allele in Caucasians may be associated with ...
Cytochrome P450 2C19 (CYP2C19) *2 (681G>A; rs4244285) and CYP2C19*3 (636G>A; rs4986893) null alleles...